Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pefloxacin→

Pefloxacin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
70458-92-3
Molecular formula
C17H20FN3O3
Molecular weight
333.36 g/mol
Drug class
Fluoroquinolone antibacterialbacterial DNA gyrase and topoisomerase IV inhibitor
Mechanism of action
Inhibits bacterial type II topoisomerases, DNA gyrase and topoisomerase IV, trapping enzyme-DNA cleavage complexes and preventing DNA replication and transcription. This produces bactericidal activity against susceptible Gram-negative and Gram-positive organisms.
Indications / reported uses
  • Historically used for susceptible systemic bacterial infections, including selected urinary, gastrointestinal and respiratory infections, where authorised.
  • Use is restricted or withdrawn in some jurisdictions because of potentially disabling and long-lasting fluoroquinolone adverse effects; follow current local authorisation and product information.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/51081 · https://antibioticdb.com/AdbCompoundDisplayForward?id=2039 · https://www.ema.europa.eu/en/news/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pefloxacin Environmental Risk Assessment (ERA) (the Pefloxacin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.